The fibroblast cells market size has grown strongly in recent years. It will grow from $0.69 billion in 2024 to $0.76 billion in 2025 at a compound annual growth rate (CAGR) of 9.8%.
This growth during the historic period was driven by the expanding use of cosmetic and anti-aging solutions, increased implementation of 3D cell culture systems, enhanced government investment in cell therapy research, a heightened awareness of personalized medicine, and broader usage in drug development and toxicity screening.
The fibroblast cells market size is expected to see strong growth in the next few years. It will grow to $1.08 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%.
This future growth will be supported by a heightened emphasis on personalized cellular therapies, increased demand for aesthetic and anti-aging treatments, wider acceptance of stem cell and regenerative medicine approaches, greater financial support for cell-based studies, and growing adoption of 3D bioprinting and organ-on-chip innovations. Key trends anticipated in the forecast period include progress in 3D cell culture technologies, novel uses in tissue repair and regenerative medicine, advancements in serum-free and defined culture media, the incorporation of artificial intelligence in cellular studies, and improved gene editing techniques for modifying fibroblasts.
The rising prevalence of various skin disorders is anticipated to drive the growth of the fibroblast cells market in the coming years. Skin disorders are conditions or diseases affecting the skin, resulting in symptoms such as rashes, itching, inflammation, redness, dryness, or lesions. This increase in skin disorders is largely attributed to growing exposure to environmental pollutants, which harm the skin barrier and lead to inflammation and greater susceptibility to skin conditions. Fibroblast cells contribute to the treatment of skin disorders by aiding tissue repair and regeneration through the production of collagen and other extracellular matrix components, which help restore the skin's strength and elasticity. For example, in February 2025, Cancer Australia, a government agency, reported 18,257 new cases of melanoma of the skin diagnosed in 2023. Consequently, the increasing prevalence of skin disorders is fueling the growth of the fibroblast cells market.
Key companies in the fibroblast cells market are focusing on developing advanced technologies, such as macrophage phenotype identification, to improve understanding of cell interactions and enhance the efficacy of fibroblast-based therapies. Macrophage phenotype identification involves distinguishing between macrophage types, primarily M1 and M2, based on their functional characteristics and molecular markers. For instance, in December 2024, Creative Biolabs, a biotechnology company based in the US, introduced Fibroblast Growth Factor 2. This product includes two versions - Fibroblast Growth Factor 2 and Fibroblast Growth Factor 2 STAB - designed to promote the proliferation of human mesenchymal stem cells (MSCs) and normal human dermal fibroblasts (NHDFs), thereby supporting advancements in stem cell and regenerative medicine research.
In October 2024, Fibrobiologics Inc., a US-based developer of fibroblast cell-based therapies for chronic diseases, entered into a partnership with Charles River Laboratories to advance regenerative therapies through scientific collaboration. This partnership aims to expedite the development and clinical readiness of fibroblast cell-based treatments, including CYWC628, by leveraging Charles River’s expertise in manufacturing and testing to support upcoming clinical trials targeting chronic conditions such as diabetic foot ulcers. Charles River Laboratories is a US-based organization that offers preclinical and clinical laboratory services, along with gene and cell therapy support.
Major players in the fibroblast cells market are Thermo Fisher Scientific Inc., Lonza Group AG, Sigma-Aldrich Corporation, Bio-Techne Corporation, STEMCELL Technologies Inc., American Type Culture Collection, Creative Bioarray, PromoCell GmbH, Coriell Institute for Medical Research, REPROCELL Inc., Axol Bioscience Ltd., ScienCell Research Laboratories Inc., Cell Applications Inc., ZenBio Inc., Cell Biologics Inc., Lifeline Cell Technology, Celprogen Inc., AMS Biotechnology (Europe) Ltd., Neuromics Inc., Evercyte GmbH, and FUJIFILM Irvine Scientific Inc.
Fibroblast cells are specialized cells located in connective tissues, playing a vital role in wound healing and tissue regeneration. These cells are responsible for producing and sustaining the extracellular matrix, which includes collagen and various structural proteins. Their primary function is to aid in tissue support and repair by synthesizing collagen and other fibers. Fibroblasts are crucial for preserving the integrity and strength of the skin and respond actively to injuries by facilitating the healing and regenerative processes.
Fibroblast cells are categorized into tissue-specific fibroblasts, disease-specific fibroblasts, and serum-free fibroblast culture medium. Tissue-specific fibroblasts are derived from healthy organs and maintain distinct characteristics of their origin, making them valuable for tissue reconstruction and accurate disease modeling. These cells are applicable across various age groups, including adults and neonates, and are used by end-users such as hospitals, clinics, academic and research institutions, and others.
The fibroblast cells market research report is one of a series of new reports that provides fibroblast cells market statistics, including the fibroblast cells industry global market size, regional shares, competitors with the fibroblast cells market share, detailed fibroblast cells market segments, market trends, opportunities, and any further data you may need to thrive in the fibroblast cells industry. This fibroblast cells market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
North America was the largest region in the fibroblast cells market in 2024. The regions covered in fibroblast cells report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the fibroblast cells market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The fibroblast cells market consists of sales of normal human fibroblasts (NHF), immortalized fibroblast cell lines, cryopreserved fibroblasts, fibroblast growth media, fibroblast differentiation kits, and 3D fibroblast culture systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
This growth during the historic period was driven by the expanding use of cosmetic and anti-aging solutions, increased implementation of 3D cell culture systems, enhanced government investment in cell therapy research, a heightened awareness of personalized medicine, and broader usage in drug development and toxicity screening.
The fibroblast cells market size is expected to see strong growth in the next few years. It will grow to $1.08 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%.
This future growth will be supported by a heightened emphasis on personalized cellular therapies, increased demand for aesthetic and anti-aging treatments, wider acceptance of stem cell and regenerative medicine approaches, greater financial support for cell-based studies, and growing adoption of 3D bioprinting and organ-on-chip innovations. Key trends anticipated in the forecast period include progress in 3D cell culture technologies, novel uses in tissue repair and regenerative medicine, advancements in serum-free and defined culture media, the incorporation of artificial intelligence in cellular studies, and improved gene editing techniques for modifying fibroblasts.
The rising prevalence of various skin disorders is anticipated to drive the growth of the fibroblast cells market in the coming years. Skin disorders are conditions or diseases affecting the skin, resulting in symptoms such as rashes, itching, inflammation, redness, dryness, or lesions. This increase in skin disorders is largely attributed to growing exposure to environmental pollutants, which harm the skin barrier and lead to inflammation and greater susceptibility to skin conditions. Fibroblast cells contribute to the treatment of skin disorders by aiding tissue repair and regeneration through the production of collagen and other extracellular matrix components, which help restore the skin's strength and elasticity. For example, in February 2025, Cancer Australia, a government agency, reported 18,257 new cases of melanoma of the skin diagnosed in 2023. Consequently, the increasing prevalence of skin disorders is fueling the growth of the fibroblast cells market.
Key companies in the fibroblast cells market are focusing on developing advanced technologies, such as macrophage phenotype identification, to improve understanding of cell interactions and enhance the efficacy of fibroblast-based therapies. Macrophage phenotype identification involves distinguishing between macrophage types, primarily M1 and M2, based on their functional characteristics and molecular markers. For instance, in December 2024, Creative Biolabs, a biotechnology company based in the US, introduced Fibroblast Growth Factor 2. This product includes two versions - Fibroblast Growth Factor 2 and Fibroblast Growth Factor 2 STAB - designed to promote the proliferation of human mesenchymal stem cells (MSCs) and normal human dermal fibroblasts (NHDFs), thereby supporting advancements in stem cell and regenerative medicine research.
In October 2024, Fibrobiologics Inc., a US-based developer of fibroblast cell-based therapies for chronic diseases, entered into a partnership with Charles River Laboratories to advance regenerative therapies through scientific collaboration. This partnership aims to expedite the development and clinical readiness of fibroblast cell-based treatments, including CYWC628, by leveraging Charles River’s expertise in manufacturing and testing to support upcoming clinical trials targeting chronic conditions such as diabetic foot ulcers. Charles River Laboratories is a US-based organization that offers preclinical and clinical laboratory services, along with gene and cell therapy support.
Major players in the fibroblast cells market are Thermo Fisher Scientific Inc., Lonza Group AG, Sigma-Aldrich Corporation, Bio-Techne Corporation, STEMCELL Technologies Inc., American Type Culture Collection, Creative Bioarray, PromoCell GmbH, Coriell Institute for Medical Research, REPROCELL Inc., Axol Bioscience Ltd., ScienCell Research Laboratories Inc., Cell Applications Inc., ZenBio Inc., Cell Biologics Inc., Lifeline Cell Technology, Celprogen Inc., AMS Biotechnology (Europe) Ltd., Neuromics Inc., Evercyte GmbH, and FUJIFILM Irvine Scientific Inc.
Fibroblast cells are specialized cells located in connective tissues, playing a vital role in wound healing and tissue regeneration. These cells are responsible for producing and sustaining the extracellular matrix, which includes collagen and various structural proteins. Their primary function is to aid in tissue support and repair by synthesizing collagen and other fibers. Fibroblasts are crucial for preserving the integrity and strength of the skin and respond actively to injuries by facilitating the healing and regenerative processes.
Fibroblast cells are categorized into tissue-specific fibroblasts, disease-specific fibroblasts, and serum-free fibroblast culture medium. Tissue-specific fibroblasts are derived from healthy organs and maintain distinct characteristics of their origin, making them valuable for tissue reconstruction and accurate disease modeling. These cells are applicable across various age groups, including adults and neonates, and are used by end-users such as hospitals, clinics, academic and research institutions, and others.
The fibroblast cells market research report is one of a series of new reports that provides fibroblast cells market statistics, including the fibroblast cells industry global market size, regional shares, competitors with the fibroblast cells market share, detailed fibroblast cells market segments, market trends, opportunities, and any further data you may need to thrive in the fibroblast cells industry. This fibroblast cells market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
North America was the largest region in the fibroblast cells market in 2024. The regions covered in fibroblast cells report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the fibroblast cells market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The fibroblast cells market consists of sales of normal human fibroblasts (NHF), immortalized fibroblast cell lines, cryopreserved fibroblasts, fibroblast growth media, fibroblast differentiation kits, and 3D fibroblast culture systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Fibroblast Cells Market Characteristics3. Fibroblast Cells Market Trends And Strategies4. Fibroblast Cells Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market32. Global Fibroblast Cells Market Competitive Benchmarking And Dashboard33. Key Mergers And Acquisitions In The Fibroblast Cells Market34. Recent Developments In The Fibroblast Cells Market
5. Global Fibroblast Cells Growth Analysis And Strategic Analysis Framework
6. Fibroblast Cells Market Segmentation
7. Fibroblast Cells Market Regional And Country Analysis
8. Asia-Pacific Fibroblast Cells Market
9. China Fibroblast Cells Market
10. India Fibroblast Cells Market
11. Japan Fibroblast Cells Market
12. Australia Fibroblast Cells Market
13. Indonesia Fibroblast Cells Market
14. South Korea Fibroblast Cells Market
15. Western Europe Fibroblast Cells Market
16. UK Fibroblast Cells Market
17. Germany Fibroblast Cells Market
18. France Fibroblast Cells Market
19. Italy Fibroblast Cells Market
20. Spain Fibroblast Cells Market
21. Eastern Europe Fibroblast Cells Market
22. Russia Fibroblast Cells Market
23. North America Fibroblast Cells Market
24. USA Fibroblast Cells Market
25. Canada Fibroblast Cells Market
26. South America Fibroblast Cells Market
27. Brazil Fibroblast Cells Market
28. Middle East Fibroblast Cells Market
29. Africa Fibroblast Cells Market
30. Fibroblast Cells Market Competitive Landscape And Company Profiles
31. Fibroblast Cells Market Other Major And Innovative Companies
35. Fibroblast Cells Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Fibroblast Cells Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on fibroblast cells market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for fibroblast cells ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The fibroblast cells market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Type: Tissue-Specific Fibroblasts; Disease-Specific Fibroblasts; Serum-Free Fibroblast Culture Medium2) By Application: Adults; Neonatal
3) By End-Users: Hospitals; Clinics; Research And Academic Institutes; Other End-Users
Subsegments:
1) By Tissue-Specific Fibroblasts: Dermal Fibroblasts; Lung Fibroblasts; Cardiac Fibroblasts; Gingival Fibroblasts; Corneal Fibroblasts; Mammary Fibroblasts; Intestinal Fibroblasts; Foreskin Fibroblasts2) By Disease-Specific Fibroblasts: Cancer-Associated Fibroblasts (CAFs); Idiopathic Pulmonary Fibrosis Fibroblasts; Scleroderma Fibroblasts; Diabetic Wound Fibroblasts; Rheumatoid Arthritis Fibroblasts; Keloid Fibroblasts; Psoriatic Fibroblasts
3) By Serum-Free Fibroblast Culture Medium: Dermal Fibroblast Medium; Lung Fibroblast Medium; Cardiac Fibroblast Medium; Cancer-Associated Fibroblast Medium; Human Gingival Fibroblast Medium; Fibroblast Growth Medium (Xeno-Free); Custom Or Defined Media For Fibroblast Expansion
Key Companies Profiled: Thermo Fisher Scientific Inc.; Lonza Group AG; Sigma-Aldrich Corporation; Bio-Techne Corporation; STEMCELL Technologies Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Thermo Fisher Scientific Inc.
- Lonza Group AG
- Sigma-Aldrich Corporation
- Bio-Techne Corporation
- STEMCELL Technologies Inc.
- American Type Culture Collection
- Creative Bioarray
- PromoCell GmbH
- Coriell Institute for Medical Research
- REPROCELL Inc.
- Axol Bioscience Ltd.
- ScienCell Research Laboratories Inc.
- Cell Applications Inc.
- ZenBio Inc.
- Cell Biologics Inc.
- Lifeline Cell Technology
- Celprogen Inc.
- AMS Biotechnology (Europe) Ltd.
- Neuromics Inc.
- Evercyte GmbH
- FUJIFILM Irvine Scientific Inc.